Affymetrix | GenomeWeb

Affymetrix

Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.

The company plans to use Thermo Fisher Scientific's newly launched PharmacoScan array-based platform for its testing.

The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.

The first six months of the year have already seen some major deals announced, including big acquisitions by Abbott and Thermo Fisher Scientific.

Three major European genomics service providers have founded a consortium to offer cost-effective, whole-genome genotyping on a new Illumina SNP array.

The GenomeWeb Index rose more than 6 percent in March, in line with the Dow and the Nasdaq, and significantly outperforming the Nasdaq Biotech Index.

After Affymetrix's shareholders approved the acquisition, Thermo Fisher was able to close the deal for a total purchase price of $1.3 billion.

The firm alleges that the company has violated certain sections of the Securities Exchange Act of 1934 in connection with its proposed sale to Thermo Fisher.

The withdrawal follows Affymetrix's statement yesterday that Origin's offer was not superior to its merger agreement with Thermo Fisher Scientific.

Pages

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.